Skip to main content

INVESTORS & MEDIA

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent News
02/25/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2020-- Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that it will present at the Cowen 2020 Health Care Conference in Boston, Mass. on Monday, March 2 at 1:30 p.m. ET . A live audio webcast of the presentation will be available under the
02/25/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2020-- Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that management will host a conference call and live audio webcast on March 2, 2020 at 8:30 a.m. ET to discuss fourth quarter and full year 2019 results and provide a general business update.
12/16/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 16, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Stephen Berenson as Chairman of its Board of Directors. Roger Pomerantz , M.D., has decided to step down after serving as Chairman of the Board since 2013. Dr.
Stock Quote
:
 
 

E-mail Alerts

Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Request Information

Obtain investor relations information by contacting us.

More

Back to top